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Hepatitis C virus (HCV) core protein forms the nucleocapsid of the HCV 21 
particle. Although many functions of core protein have been reported, how the HCV 22 
particle is assembled is not well understood. Here we show that the nucelocapsid-like 23 
particle of HCV is composed of a disulfide-bonded core complex (dbc-complex). We 24 
also found that the disulfide-bonded dimer of the core (dbd-core) is formed at the 25 
endoplasmic reticulum (ER) where the core protein is initially produced and processed. 26 
Mutational analysis revealed that the cysteine residue at amino-acid position 128 27 
(Cys128) of the core, a highly conserved residues among almost all reported isolates, is 28 
responsible for dbd-core formation and virus-like particle production with no effect on 29 
the replication of HCV RNA genome and the several known functions of the core, 30 
including RNA binding ability and localization to the lipid droplet. The Cys128 mutant 31 
core showed a dominant-negative effect in terms of HCV-like particle production. These 32 
results suggest that this disulfide bond is critical for the HCV virion. We also obtained 33 
the results that the dbc-complex in the nucleocapsid-like structure was sensitive against 34 
proteinase K but not trypsin digestion, suggesting that the capsid is built up of a tightly 35 





Hepatitis C virus (HCV) infection is a major cause of chronic hepatitis, liver 39 
cirrhosis, and hepatocellular carcinoma, affecting approximately 200 million people 40 
worldwide (13, 29, 44). Current treatment strategies, including interferon coupled with 41 
ribavirin, are not effective for all patients infected with HCV. An error-prone replication 42 
strategy allows HCV to undergo rapid mutational evolution in response to immune 43 
pressure, and thus evade adaptive immune responses (10). New approaches to HCV 44 
therapy include the development of specifically targeted antiviral therapies for hepatitis 45 
C (STAT-Cs), which target such HCV proteins as NS3/4A, serine protease, and the 46 
RNA-dependent RNA polymerase NS5B (3). Despite potent antiviral activity for some 47 
of these approaches, many resistant HCV strains have been reported after treatment with 48 
existing STAT-Cs (23, 48, 51). Therefore, identification of new targets that are common 49 
to all HCV strains and are associated with low mutation rates is an area of active 50 
research. 51 
HCV has a 9.6-kb, plus-strand RNA genome composed of a 5’-untranslated 52 
region (UTR), an open reading frame that encodes a single polyprotein of about 3000 53 
amino acids, and a 3’-UTR. The polyprotein is processed by host and viral proteases to 54 
produce three structural proteins (core, E1, and E2) and seven nonstructural proteins (p7, 55 
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NS2, NS3, NS4A, NS4B, NS5A, and NS5B) (14, 16, 17, 22, 49). HCV core protein is 56 
produced co-translationally via carboxyl (C)-terminal cleavage to generate an immature 57 
core protein, 191 amino acids in length, on the endoplasmic reticulum (ER) (16). This 58 
protein consists of three predicted domains: the N-terminal hydrophilic domain (D1), 59 
the C-terminal hydrophobic domain (D2), and the tail domain (33), which serves as a 60 
signal peptide for the E1 envelope protein. The D1 includes a number of positively 61 
charged amino acids responsible for viral RNA binding (amino acids 1-75) (43) and the 62 
region involved in multimerization of core via homotypic interactions (amino acids 63 
36-91 and 82-102) (32, 40) (Supplementary Fig. 1). The hydrophobic D2 includes the 64 
region responsible for core association with lipid droplets (LDs) (amino acids 125-144) 65 
(7, 18, 37), which accumulate in response to core production (1, 6). 66 
Many functions of core protein have been reported (13, 38, 50). Yet because 67 
infectious HCV particles cannot be appropriately produced in currently available 68 
experimental systems, HCV particle assembly has not been elucidated to date. A cell 69 
culture system that reproduces the complete lifecycle of HCV in vitro was developed by 70 
Wakita et al. using a cloned HCV genome (JFH1) (53). Using this system, the assembly 71 
of infectious HCV particles was found to occur near LDs and ER-derived LD-associated 72 
membranes (36, 47). Neither the structures nor functions of the virus proteins involved 73 
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in virus particle assembly are known, however. To elucidate this point, we have 74 
analyzed the biochemical characteristics of the proteins within the fraction containing 75 
the HCV particle, and found a disulfide-bonded core protein complex. We revealed that 76 
the disulfide-bonded dimer of core (dbd-core) was formed by a single cysteine residue 77 
at amino-acid position 128 on the ER. The roles of the disulfide bond of the core in the 78 
virus-like particle formation are discussed in this paper. 79 
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MATERIALS AND METHODS 80 
Cell culture: The HuH-7 and HuH-7.5 human hepatoma cell lines were grown in 81 
Dulbecco’s modified Eagle’s medium (Nacalai Tesque, Kyoto, Japan) supplemented 82 
with 10% fetal bovine serum, 100 U/ml nonessential amino acids (Invitrogen, Carlsbad, 83 
CA), and 100 g/ml each penicillin and streptomycin sulfate (Invitrogen). 84 
 85 
Antibodies: The antibodies used for immunoblotting and indirect immunofluorescence 86 
analysis were specific for core (#32-1), FLAG M2 (Sigma-Aldrich, St Louis, MO), 87 
c-myc (Sigma-Aldrich), NS5A (CL1), ADRP (StressGen, Victoria, Canada), 88 
Calnexin-NT (StressGen), and GAPDH (Chemicon, Temecula, CA). Antibodies 89 
specific for core (#32-1) were a gift from Dr Kohara (The Tokyo Metropolitan Institute 90 
of Medical Science, Japan). Rabbit polyclonal anti-NS5A CL1 antibodies have been 91 
described previously (36).  92 
 93 
Plasmid construction: All plasmids were generated by inserting PCR-amplified 94 
fragments into expression plasmids. The plasmids, primer sequences, templates for the 95 
PCRs, and restriction enzyme sites used to construct the plasmids are listed in 96 
Supplementary Table. Plasmids pJFH1
E2FL
 (full-length HCV genome with FLAG 97 
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epitope in E2 HVR), pJFH1
AAA99
 (encoding a NS5A mutant of JFH1
E2FL
, resulting in 98 
non-infectious HCV particles), pJFH1
PP/AA
 (encoding a core mutant of JFH1
E2FL
, which 99 
allows replication in cells but prevents HCV particle production), and pcDNA3-core
WT
 100 
(expression plasmid encoding full-length JFH1 core) have been previously described 101 
(36). Plasmid pJ6/JFH1, which contains the full-length HCV genome encoding 102 
structural proteins from the J6 strain and nonstructural proteins from the JFH1 strain, 103 
was kindly provided by Charles M. Rice (The Rockefeller University, New York, USA). 104 
 105 
In vitro transcription: RNA for transfection was synthesized as described previously 106 
(36). In brief, plasmids carrying the HCV RNA sequence were linearized with XbaI and 107 
used as templates for in vitro transcription with MEGAscript T7 (Ambion, Austin, TX). 108 
 109 








, or 110 
JFH
AAA99
 and J6/JFH1 or J6/JFH1
AAA99
 RNA were transfected into HuH-7 and HuH-7.5 111 
cells (1.0 × 10
7
 cells) by electroporation (260 V, 0.95 F) using a GENE PULSER II 112 
system (BioRad, Hercules, CA). Core expression plasmids were transfected into HuH-7 113 




HCV particle precipitation: Culture medium from HCV RNA–transfected cells were 116 
concentrated using Amicon Ultra-15 centrifugal filters with Ultracell-100 membranes 117 
(Millipore, Billerica, MA) and mixed with sucrose solution in PBS to a final sucrose 118 
concentration of 2%. This mixture was ultracentrifuged (100,000 × g; 4°C for 2 h) and 119 
the HCV particles were obtained as a pellet. The pellet was then suspended in culture 120 
medium for infection experiments or PBS for immunoblot analysis. 121 
 122 
Indirect immunofluorescence analysis: Indirect immunofluorescence analyses of 123 
HCV infection and the cellular localization of HCV proteins were performed as 124 
described previously (36). 125 
 126 
Protease protection assay: Concentrated culture medium from JFH1
E2FL
 127 
RNA–transfected HuH-7 cells was fractionated using 20~50% sucrose density gradients 128 
and the HCV RNA titer was measured in quantitative RT-PCRs as described below. 129 
Fractions with high HCV RNA titers were collected and JFH1
E2FL
 particles were 130 
obtained as a pellet after ultracentrifugation (100,000 × g; 4°C for 2 h). The pellet was 131 
suspended in PBS and treated with 10 g/ml trypsin or 5 g/ml proteinase K in the 132 
presence or absence of 1% NP-40 at 37°C for 15 min, respectively, unless otherwise 133 
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indicated. The reaction was quenched by the addition of protease inhibitor cocktail 134 
(Nacalai Tesque) followed by SDS-PAGE under non-reducing conditions and 135 
immunoblotting specific for core protein. 136 
 137 
Immunoblot analysis: Samples were subjected to SDS-PAGE in sample buffer (62.5 138 
mM Tris-HCl [pH 7.8], 1% SDS, and 10% glycerol) with or without 5% -ME or 50 139 
mM DTT for reducing or non-reducing conditions, respectively. N-ethylmaleimide 140 
(NEM) (Nacalai Tesque) was added to the sample buffer to final concentration of 5 mM 141 
in indicated samples. Proteins were transferred to polyvinylidene difluoride membrane, 142 
and blocked in blocking buffer for 1 h at room temperature with gentle agitation. After 143 
incubation with primary antibodies overnight at 4°C, the membrane was washed three 144 
times for 5 min in washing buffer at RT with gentle agitation. Then, the membrane was 145 
incubated with HRP-conjugated secondary antibodies for 1 h at RT. After three washes 146 
in washing buffer, proteins were detected using Western Lightning (PerkinElmer, 147 
Waltham, MA) or ECL Advance (GE Healthcare, Buckinghamshire, England) and 148 
Kodak MXJB plus medical X-ray film (Kodak, Rochester, NY) or an LAS-4000 system 149 




Preparation of LDs: LDs were prepared as described previously (36). 152 
 153 
Preparation of MMFs: MMFs were collected as previously described (15) with some 154 
modifications. In brief, cells were collected in homogenization buffer (20 mM Tris-HCl 155 
[pH 7.8], 250 mM sucrose, and 0.1% ethanol supplemented with protease inhibitor 156 
cocktail) and homogenized on ice using 40 strokes of a dounce homogenizer. The 157 
samples were then centrifuged at 1000 × g for 10 min at 4°C. Supernatant was collected 158 
in a new tube and centrifuged again at 16,000 × g for 20 min at 4°C. Supernatant was 159 
further centrifuged at 100,000 × g for 60 min at 4°C. The MMF precipitate was 160 
homogenized in lysis buffer (1% NP-40, 0.1% SDS, 20 mM Tris-HCl [pH 8.0], 150 161 
mM NaCl, 1 mM EDTA, and 10% glycerol supplemented with protease inhibitor 162 
cocktail) using a dounce homogenizer. 163 
 164 
Quantitative reverse transcription (qRT)-PCR analysis: qRT-PCR analysis for the 165 
HCV RNA titer was performed as described previously (36). 166 
 167 
Enzyme-linked immunosorbent assay (ELISA) specific for core: Core in culture 168 
medium was quantified using an ELISA according to the manufacturer’s protocol (HCV 169 
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antigen ELISA test; Ortho-Clinical Diagnostics, Raritan, NJ). 170 
 171 









, respectively, using the TNT Coupled 173 
Rabbit Reticulocyte Lysate system (Promega, Madison, WI) according to the 174 
manufacturer’s protocol. These proteins were incubated with poly-U agarose (Sigma) in 175 
50 mM HEPES (pH 7.4), 100 mM NaCl, 0.1% NP-40, and 20 U RNase inhibitor at 4°C 176 





The HCV particle contains core complex formed by a disulfide bond 180 
To analyze the core protein of the HCV particle, we first subjected the 181 
concentrated culture medium of HuH-7 cells transfected with in vitro transcribed 182 
JFH1
E2FL
 RNA to ultracentrifugation. After the resulting pellet was resuspended in 183 
culture medium, we confirmed the presence of infectious HCV particles based on 184 
infectivity against HuH-7.5 cells (Fig. 1a). The infectious JFH1
E2FL
 particle–containing 185 
pellet was separated by SDS-PAGE under non-reducing conditions, and immunoblot 186 
analysis showed the presence of a core antibody–reactive protein that was 187 
approximately twice the size of core (38 kDa), in addition to the expected 19-kDa core 188 
protein (Fig. 1b, lane 1). Because treatment with dithiothreitol (DTT) eliminated the 189 
larger core antibody–reactive band while levels of core monomer increased (Fig. 1b, 190 
lanes 2-6), the larger protein likely represented a core-containing complex formed by 191 
disulfide bonds. This complex was also found in J6/JFH1-derived particles 192 
(Supplementary Fig. 2), indicating that the complex was not specific for JFH1
E2FL
. 193 
To determine whether the core complex is a component of the HCV particle, a 194 
protease protection assay was performed using RNase-resistant HCV particles 195 
fractionated based on buoyant density. Concentrated culture medium from HuH-7 cells 196 
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transfected with in vitro transcribed JFH1
E2FL
 RNA were fractionated using a 20-50% 197 
sucrose density gradient and JFH1
E2FL
 particles which were presumed to contain both 198 
infectious and non-infectious particles, were collected from fractions with high HCV 199 
RNA titers using ultracentrifugation (Fig. 2a, fraction #8 to #13). The core protein from 200 
the collected fractions was analyzed by immunoblotting after SDS-PAGE under the 201 
non-reducing condition, showing only the core complex (Fig. 1c, right panel).  202 
To examine whether the complex contributes to the infectivity of the particles, 203 
we analyzed the core complex in the fractions containing infectious and non-infectious 204 
HCV particles (fraction #9 and #11 of Fig. 2a, filled and open arrowheads, respectively). 205 
Both infectious and non-infectious HCV particle containing fraction consists the core 206 
complex (Fig. 2b). To confirm this further, a pellet containing mutant JFH1
AAA99
 207 
particles—a mutant of JFH1E2FL that produces primarily non-infectious particles 208 
(36)—was analyzed in a similar manner. These core complexes were found in both 209 




 which was a mutant J6/JFH1 with 210 
similar substitution to JFH1
AAA99
 (Supplementary Fig. 2). These results indicated that 211 
the core complex was present in both the infectious and non-infectious HCV-like 212 
particles. 213 
The core monomer observed in the pellet samples (Fig. 1b) may be from the 214 
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secreted core or the debris of apoptotic cells, because the core is known to be secreted 215 
from cells expressing this protein under particular conditions (42), and JFH1 strain is 216 
known to cause apoptosis (45). The core complex–specific signals in the HCV particles 217 
seem to be increased with the NP-40 treated samples for some unknown reason (Fig. 1c; 218 
lanes 1 and 2). Although the intermolecular disulfide bond is known to be artificially 219 
formed in denaturing SDS-PAGE in the absence of reducing agents, the core complex 220 
was still observed even in the presence of NEM, which is alkylating agent for free 221 
sulfhydryls, during sample preparation (Fig. 2c), indicating that the core complex was 222 
naturally present in the virus-like particles. 223 
The HCV nucleocapsid is covered with lipid membranes and E1 and E2 224 
envelope proteins, making it resistant to proteases. As expected, in the absence of 225 
NP-40, the core complex was resistant to proteinase K (Fig. 1c, lane 3), whereas 226 
proteinase K was able to digest core protein in whole-cell lysates collected from 227 
JFH1
E2FL
-transfected HuH-7 cells (Fig. 1c, left panel). Disrupting the envelope structure 228 
with NP-40 made the core complex susceptible to proteinase K treatment (Fig. 1c, lane 229 
4), indicating that the core complex was indeed a component of the HCV particle. 230 
 231 
The disulfide-bonded core complex (dbc-complex) forms on the ER 232 
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To investigate the subcellular site at which the dbc-complex forms, LD and 233 
microsomal membrane fractions (MMFs) from JFH1
E2FL
 replicating HuH-7 cells were 234 
analyzed by immunoblotting. We first analyzed the dbc-complex in LDs, because the 235 
LD is involved in infectious HCV particle formation (36, 47). The purity of the LD 236 
fraction was determined using immunoblot analysis of calnexin and adipocyte 237 
differentiation-related protein (ADRP), an ER and an LD marker protein, respectively 238 
(Fig. 3a, upper panel). The core protein was then analyzed in the LD fraction. As shown 239 
in Figure 3a (lower panel), the dbc-complex was observed in the LD fraction from 240 
JFH1
E2FL
 RNA–transfected HuH-7 cells. We next analyzed the core protein in the 241 
ER-containing MMF, because the core protein is first translated and processed on the 242 
ER (16). As shown in Figure 3b, the dbc-complex was observed in the MMF from 243 
JFH1
E2FL
 RNA–transfected HuH-7 cells. These results suggest that the dbc-complex is 244 
first formed at the ER. To assess the possibility that dbc-complex-containing HCV 245 
particles were also assembled on the ER, the sensitivity of the dbc-complex to protease 246 
treatment was analyzed. The dbc-complex in the MMF was susceptible to protease 247 
treatment in the absence of NP-40, indicating that the dbc-complex on the ER was not 248 




dbc-Complex is most likely a disulfide-bonded dimer form of the core 251 
In order to examine whether the core itself have a potential to form 252 
dbc-complex, we analyzed dbc-complex formation of full length wild-type core 253 
(core
WT
) expressed from pcDNA3-core
WT
 (36), the expression plasmid encoding 191 254 
amino acid full length core of JFH1 strain. We used this expression plasmid because the 255 
core from this plasmid was likely to be processed correctly enough to produce 256 
infectious HCV particles when co-transfected with JFH1
dc3
 RNA, which is a core 257 
deletion mutant of JFH1 (36). As results, the dbc-complex formation was observed from 258 
the MMF of core
WT
 expressing cells both in the absence and the presence of NEM (Fig. 259 
4b; lane 2 and data not shown, respectively). We next investigated the effect of the 260 
amino acid region of E1 on the production of dbc-complex, because it has been reported 261 
that the efficient processing of core protein is dependent on the presence of some E1 262 
sequence to ensure the insertion of the signal sequence for E1 in the 263 
translocon/membrane machinery (34). Then the dbc-complex was also observed when 264 
the core was expressed from a pcDNA3-C-E1/25, which encodes the full length core 265 
followed by the N-terminal 25 amino acid sequence of E1 to ensure that the core is 266 
processed properly (Supplementary Fig. 3a). These data showed that the dbc-complex 267 
was formed by expression of the core protein only in the cells. 268 
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Next, we examined the structural components of the dbc-complex. Because the 269 
dbc-complex was twice the size of a core monomer, it likely was disulfide-bonded 270 
dimer form of the core (dbd-core). So, we investigated whether the core molecules with 271 
different tags were able to form the dbd-core. We first generated expression plasmids 272 
encoding core with the N-terminal FLAG and Myc tags (pcDNA3-FLAG-core and 273 
pcDNA3-Myc-core, respectively; Fig. 4a). The tagged core proteins were expressed or 274 
co-expressed with core
WT
 in HuH-7 cells and the MMF was analyzed by SDS-PAGE. 275 
The FLAG or Myc tag shifted the positions of the monomer and the complex bands (Fig. 276 
4b; lanes 3 and 4), compared with the core
WT
 (Fig. 4b; lane 2). When the core
WT
 was 277 
co-expressed with FLAG-core or Myc-core, the core complex with an intermediately 278 
size was observed in addition to the bands obtained when the constructs were 279 
independently expressed (Fig. 4b; lanes 5 and 6, filled arrows); the intermediate band 280 
disappeared after treatment with -mercaptoethanol (-ME) (Supplementary Fig. 3b; 281 
lanes 11 and 12, filled arrows), indicating that core
WT
 and tagged core formed a 282 
heteromeric disulfide-bonded dimer. These results demonstrated that the dbc-complex 283 
on the ER is a dbd-core. Although we tried to detect the hetero-/homo-dimer consisting 284 
the tagged-core by using anti-FLAG or anti-Myc antibodies, these dimers but the 285 
monomeric forms of the tagged-core were not detected, possibly because of the less 286 
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sensitivity and specificity of the antibodies compared to the anti-core antibody we used 287 
especially against epitopes in the dbd-core. Above results coupled with the similarity of 288 
the molecular size and sensitivity against -ME and DTT, suggested the dbc-complex in 289 
the HCV particle is most likely a dbd-core. 290 
 291 
Core cysteine residue 128 (Cys128) mediates dbd-core formation 292 
Our results showed that core from JFH1
E2FL
 forms a disulfide-bonded dimer on 293 
the ER. A search for cysteine residues in JFH1
E2FL
 core identified amino-acid positions 294 
128 (Cys128) and 184 (Cys184) (Supplementary Fig. 1). These residues are highly 295 
conserved in core proteins from the approximately 2000 reported HCV strains (HCVdb, 296 
http://www.hcvdb.org/; Hepatitis Virus Database; http://s2as02.genes.nig.ac.jp/). To 297 
determine which cysteine residue meditated disulfide bond formation, we generated 298 
point mutations in JFH1
E2FL
 that substituted Cys128 and/or Cys184 with Alanine (Ala) 299 






, respectively; 300 




 failed 301 
to form a dbd-core under non-reducing condition, whereas core protein from JFH1
C184A
 302 
formed the dimer, indicating that Cys128 was the responsible residue. Similar results 303 
were observed when Cys was substituted to Serine (Ser) instead of Ala 304 
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(Supplementary Fig. 5c). Recently, Majeau et al. reported that the core protein of 305 
J6/JFH1 strain with Cys128 substitutions to Ala or Ser were instable in both Pichia 306 
pastoris and human hepatoma cell line HuH-7.5 (31), although we did not detect any 307 
noticeable degradation of the mutant cores of JFH1 strain (Fig. 5b and Supplementary 308 
Fig. 5c). This difference may resulted from difference in sample preparation as we used 309 
full length genome of JFH1
E2FL
 strain, bearing JFH1 strain core, and HuH-7 cells 310 
instead of core expressing plasmid for J6 strain and HuH-7.5. 311 
To exclude the possibility that mutation of Cys128 inhibited dbd-core 312 





, respectively) were created and examined for the effects on 314 
dbd-core formation and infectious virus particle production. These mutants formed 315 
dbd-core and infectious HCV particles were detected in the culture medium 316 
(Supplementary Fig. 4a-c), supporting an essential role for Cys128 in dbd-core and 317 
particle formation. 318 
 319 
dbd-Core contributes to HCV particle production 320 
To examine the functional roles of dbd-core, infectious HCV particle 321 
production, HCV replication efficiency, co-localization of core and the LD, and 322 
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RNA-binding of mutant and wild-type (JFH1
E2FL
) core were evaluated. Culture medium 323 




 RNA contained 324 





 RNA (Fig. 5c). We also found significant decreases in the levels 326 





 RNA (Fig. 5d, e). Similar results were observed with 328 
J6/JFH1 C128A or C128/184A mutant strain (data not shown). To investigate whether 329 
these results were due to suppressed HCV replication, HCV RNA and protein levels in 330 
cells transfected with mutant RNA were analyzed using qRT-PCR and immunoblot 331 
analyses, respectively. Compared with results obtained with JFH1
E2FL
, no significant 332 
changes were observed in the cellular HCV RNA titer at days 1, 3 and 5 333 
post-transfection or in the expression of the HCV nonstructural protein NS5A (Fig. 6a, 334 
b). This indicated that substitution of Cys128 did not significantly affect HCV RNA 335 
genome replication or viral protein production, demonstrating that the dbd-core 336 
functions during HCV particle production rather than HCV genome replication. Similar 337 
results were observed using RNA of JFH1 mutant strain which Cysteine of position 128 338 
were substituted to Ser instead of Ala; JFH1
C128S
 (Supplementary Fig. 5a, b, d). 339 
The subcellular localizations of core and NS5A in HuH-7 cells transfected with 340 
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HCV RNA were investigated using indirect immunofluorescence and confocal 341 
microscopy, because recruiting HCV proteins to the LD is an important step in 342 
infectious HCV particle production (36, 47) and core trafficking to the LD is dependent 343 
on SPP-mediated cleavage of the tail region (34, 41). JFH1
C128A
 mutant core and NS5A 344 
were efficiently trafficked to the LD, as was observed with wild-type JHF1
E2FL
 (Fig. 6c), 345 
suggesting that SPP cleavage and core maturation were not affected by the C128A 346 
mutation. Similar results were obtained with core derived from JFH1
C184A
 and 347 
JFH1
C128/184A
 (Supplementary Fig. 6), and also, Ser mutant JFH1
C128S
 (Supplementary 348 
Fig. 5e). 349 
Because HCV core protein can bind RNA, including the HCV genome during 350 









 similarly 352 
bound with poly-U resin (Fig. 6d). 353 
 354 
dbd-Core is important for HCV particle assembly 355 




 similarly 356 
localize to LDs, recruit NS proteins to the LD, and bind to RNA. Moreover, this 357 
mutation did not markedly affect HCV genome replication. How does core
C128A
 affect 358 
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the production of HCV particles? An important function of core protein is 359 
multimerization, which is followed by capsid construction and packaging of the RNA 360 
genome in the viral particles. We therefore determined whether core
C128A
 had a 361 
dominant-negative effect on virus-like particle production. Wild-type JFH1
E2FL
 RNA 362 
and different amounts of JFH1
C128A
 RNA were co-transfected into HuH-7 cells and the 363 
HCV RNA titer and infectivity of the virus-like particles in the culture medium were 364 
analyzed. As expected, the HCV RNA titer in the cells increased with higher levels of 365 
transfected RNA (Supplementary Fig. 7a). In contrast, the HCV RNA titer and 366 
infectivity in the culture medium decreased in a JFH1
C128A
 RNA dose–dependent 367 
manner when this mutant RNA was co-transfected with wild-type RNA (Fig. 7a, b). 368 
This suppressive effect was not observed when either wild-type RNA or core deletion 369 
mutant JFH1
dc3
 RNA was used instead of mutant RNA in a similar experiment 370 
(Supplementary Fig. 7b-e), indicating that higher levels of HCV RNA alone did not 371 
inhibit HCV particle production. Thus, core
C128A
 had a dominant-negative effect on 372 
HCV particle production. Together, these results suggest that dbd-core is involved in the 373 
assembly of HCV particles. 374 
 375 
The nucleocapsid-like particle of HCV was resistant to trypsin treatment 376 
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To further investigate the structure of the HCV nucleocapsid-like particle most 377 
likely formed by dbd-core, we examined the sensitivity of the particle to trypsin, which 378 
cleaves polypeptides at the C-terminal end of basic residues. Whereas trypsin digested 379 
core in the whole-cell lysates (Fig. 8a, left panel), dbd-core from buoyant 380 
density–fractionated JFH1E2FL particles was resistant to digestion despite NP-40 381 
treatment (Fig. 8a, right panel), although it was sensitive to proteinase K which have a 382 
broad specificity (Fig. 1c). The N-terminal hydrophilic domain of the core protein 383 
(from residues 6-121) contains a number of trypsin cleavage sites (25 sites, in JHF1 384 
strain) (Supplementary Fig. 1), suggesting that the N-terminal domain faces inward 385 
and/or the conformation prevents protease access. To address this idea, buoyant 386 
density–fractionated JFH1E2FL particles were treated with trypsin under more strict 387 
conditions in the presence of NP-40. Cleavage of dbd-core by various levels of trypsin 388 
correlated with the appearance of a shorter molecule (Fig. 8b, white arrowhead). The 389 
shorter molecule was presumed to be partially digested dbd-core with an intact 390 
N-terminal region because it was recognized by anti-core antibodies, which bind an 391 
epitope located in amino-acids 20-40 of core (personal communication from Dr. M. 392 
Kohara, The Tokyo Metropolitan Institute of Medical Science, Japan). These results 393 
suggest that dbd-core is assembled into the nucleocapsid-like particle such that most of 394 
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In this study, we have shown that the nucleocapsid-like particle of HCV 397 
contains most likely a dimer of core protein that is stabilized by a disulfide bond. 398 
Mutational analysis revealed that Cys128 forms the disulfide bond between core 399 
monomers. Several reports have shown that disulfide bonds in the capsid proteins of 400 
some viruses are involved in virus particle assembly and stabilization of the viral capsid 401 
structure (4, 21, 27, 28, 57); these viruses are characterized by icosahedral 402 
nucleocapsids. Because, like these viruses, the HCV virion is spherical (2, 20), it has 403 
been suggested that HCV may contain a nucleocapsid with a similar structure (20). We 404 
found the dbc-complex which is most likely to be the dbd-core in JFH1
E2FL
 virus-like 405 
particles (Figs. 1c and 8a). The dbd-core in the capsid structure was digested by 406 
proteinase K but not trypsin in the presence of NP-40 (Figs. 1c and 8a, lane 4). The 407 
resistance to trypsin suggested a tight conformation for dbd-core in the capsid with no 408 
exposed trypsin cleavage sites. The truncated form of dbd-core that was observed under 409 
certain trypsin treatment conditions likely resulted from cleavage in the C-terminal 410 
portion of the protein (e.g., arginine residues at positions 149 and 156) (Supplementary 411 
Fig. 1), although it is possible that the truncation of dbd-core was due to non-specific 412 
cleavage by trypsin. These results imply that dbd-core is configured such that the N- 413 
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and C-terminal ends are located at the inner and outer surface of the capsid, respectively. 414 
Because the N-terminal region of core includes the RNA binding domain (43), the HCV 415 
RNA genome likely interacts with core as it is packed in the nucleocapsid. On the other 416 
hand, the C-terminal hydrophobic domain probably faces the lipid membranes to form 417 
the envelope structure. Only part of the N-terminal hydrophilic region of the core 418 
protein has been structurally examined using X-ray crystal structural analysis (35), and 419 
using structural bioinformatics and nuclear magnetic resonance analysis (11). Although 420 
the C-terminal half of core has been structurally investigated by bioinformatics (8), the 421 
3D structure containing the Cys128 residue is unknown. Thus, determination of the 422 
structure of the core in the nucleocapsid containing Cys128 residue should be required 423 
for understanding the whole structure of this protein in the virus particles. 424 
Because co-transfection of JFH1
C128A
 RNA with wild-type JFH1
E2FL
 RNA 425 
inhibited particle production in a mutant RNA dose-dependent manner (Fig. 7a, b), the 426 
C128A core variant clearly inhibited HCV particle formation by wild-type core. Cys128 427 
was also reported previously to be a residue included in the region important for the 428 
production of infectious HCV (39). This residue is located near the N-terminal end of 429 
the hydrophobic region of the core (amino acids 122-177) and belongs to the 430 
hydrophilic side of an amphipathic helix expected to interact in-plane of the membrane 431 
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interface (7). Therefore, it is possible to think that the dbd-core formation via Cys128 432 
can stabilize the interaction between core and the membranes. The N-terminal half of 433 
core (amino acids 1-124) reportedly assembles into nucleocapsid-like particles in the 434 
presence of 5’-UTR from HCV RNA (24), suggesting that some nucleocapsid-like 435 
particles may assemble via only homotypic interactions from the core protein. In 436 
addition to weak homotypic interactions, the HCV core protein forms a disulfide bond 437 
to stabilize the capsid structure, thus making dbd-core indispensable in the stable 438 
virus-like particle. We observed that culture medium from JFH1
C128A
 or 439 
JFH1
C128S
-transfected cells included slight infectivity (Fig. 5c or Supplementary Fig. 440 
5d). This made us speculate that this mutant may produce some infective particle-like 441 
structure formed by homotypic interaction of the core. Such a slight infectivity may 442 
have reflected the optimized in vitro culture conditions compared with in vivo 443 
conditions, allowing relatively unstable virus particles to survive. 444 
A nucleocapsid must be resistant to environmental degradation, yet still be able 445 
to disassemble after infection. Disulfide bonds could help with these process by 446 
switching between a stable and unstable virus capsid based on different intracellular and 447 
extracellular oxidation conditions (12, 30). During the virus life cycle, the disulfide 448 
bond strengthens the viral capsid structure and protects the viral genome from oxidative 449 
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conditions and cellular nucleases when virus particles are formed. Upon infection, the 450 
disulfide bond may be cleaved under cytoplasmic reducing conditions, thereby releasing 451 
the viral genome into the cell for replication. HCV may utilize the core protein disulfide 452 
bond in this way as HCV enters the host cell via clathrin-mediated endocytosis (5) into 453 
a low-pH, endosomal compartment (25, 52); this is presumably followed by endosomal 454 
membrane fusion and release of the viral capsid into the cytoplasm (38). 455 
Treatment of HCV with pegylated interferon in combination with ribavirin is 456 
not effective for all patients. Recently, drugs targeting the viral proteins NS3/4A and 457 
NS5B have been examined in clinical trials. Although these drugs are relatively specific, 458 
resulting in fewer side effects and potent antiviral activity, monotherapy can be 459 
complicated by rapidly emerging resistant variants, carrying mutations that reduce drug 460 
efficacy, perhaps due to conformational changes in the target (23, 48, 51). Therefore, 461 
viral proteins that are highly conserved among strains and those characterized by low 462 
mutation rates may be better targets for drug development. Because the core protein is 463 
the most conserved HCV protein and Cys128 is conserved among almost all examined 464 
HCV strains, drugs that interact with Cys128 and/or region around or near this residue 465 
will likely show broad spectrum efficacy to block the stable infectious particle 466 
formation. Structural analysis of dbd-core should aid the development of new STAT-Cs 467 
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that target Cys128 by direct interaction with the sulfide group and/or region around this 468 
residue. Until now and still, the mechanism of disulfide bond formation of core on the 469 
ER is unknown. Dimerization of capsid protein by disulfide bond has been reported in 470 
some enveloped viruses (9, 19, 54, 56), although some were shown not to be important 471 
for virus particle formation (26, 55). Unlike the vaccinia virus (46), no redox system of 472 
its own has been reported for these viruses. Therefore, further investigations addressing 473 
the mechanisms underlying dbd-core formation on the ER may reveal new mechanism 474 
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FIGURE LEGENDS 629 
Figure 1. The HCV-like particle consists of a core complex formed by a disulfide bond. 630 
(a) The infectivity of the pellet fraction collected from concentrated culture medium 631 
from JFH1
E2FL
 RNA–transfected HuH-7 cells was analyzed as described in the 632 
Materials and Methods. ―input‖ represents the same volume of concentrated culture 633 
medium used to pellet the virus-like particles. (b) Immunoblot analysis of the core in 634 
pellets containing JFH1
E2FL
 virus particles treated with various levels of DTT (lanes 1, 2, 635 
3, 4, 5 and 6 represent 0, 1.56, 3.13, 6.25, 12.5 and 25 mM, respectively). (c) 636 
Immunoblot analysis of core in JFH1
E2FL
 particles collected from sucrose density 637 
gradient fractions with high HCV RNA titers (particle) (Fig. 2a, fraction #8 to #13) and 638 
treated with 5 g/ml proteinase K at 3°C for 15 min in the presence or absence of 1% 639 
NP-40 (right panel). As a positive control, whole-cell lysate (WCL) prepared from 640 
JFH1
E2FL
 RNA–transfected HuH-7 cells in lysis buffer was treated with 5 g/ml 641 
proteinase K at 37°C for 15 min (left panel). Data are representative of three 642 
independent experiments. 643 
 644 
Figure 2. HCV nucleocapsid-like particle consists of core complex. (a) HCV RNA titer 645 
in culture medium separated on a 20-50% sucrose density gradient. Concentrated 646 
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culture medium from JFH1
E2FL
 RNA–transfected HuH-7 cells were treated with RNase 647 
and separated on a 20-50% sucrose density gradient. Fractions were obtained from the 648 
bottom to the top of the tube (#1 to #16). The HCV RNA titer and infectivity of each 649 
fraction were analyzed by real-time qRT-PCR (for fraction #1 to #16) and counting the 650 
number of cells infected with HCV-like particle detected by immunofluorecense (for 651 
fraction #3 to #14) as described in Materials and Methods, respectively. In brief, each 652 
fraction were diluted with 1x PBS and HCV-like particles were collected by 653 
ultracentrifugation, then pellets were suspended in culturing medium and used for 654 
infection. (b) HCV-like particle collected from infectious (Fig. 2a, filled arrowhead) 655 
and HCV RNA (Fig. 2a, open arrowhead) peaks were collected by ultracentrifugation 656 
and subjected to non-reducing SDS-PAGE and detected by immunoblot against core. (c) 657 
HCV-like particle collected from fraction #8 to #13 (a) were subjected to non-reducing 658 
SDS-PAGE in the presence (+) or absence (-) of 5 mM N-ethylemaleimide (NEM) and 659 
analyzed by immunoblotting against the core. Data are representative of two (a, 660 
infectivity of fractions) or three independent experiments. 661 
 662 
Figure 3. The core complex is formed at the LD and ER. (a) The LD fraction and 663 
whole-cell lysate (WCL) were collected from JFH1
E2FL
 RNA–transfected HuH-7 cells 664 
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on day 5 post-transfection. Immunoblot analysis of the LD marker adipose 665 
differentiation-related protein (ADRP) and the ER marker calnexin in the LD fraction 666 
(upper panel). Immunoblot analysis of core in the LD fraction treated with or without 50 667 
mM DTT (lower panel). (b) Immunoblot analysis of core protein in the MMF and WCL 668 
collected from JFH1
E2FL
-producing HuH-7 cells on day 5 post-transfection in the 669 
presence or absence of 5% -mercaptoethanol (-ME). Data are representative of three 670 
independent experiments. 671 
 672 
Figure 4. The core complex consists of a core dimer. (a) Schematic of wild-type, 673 
FLAG-tagged (FLAG-core), and Myc-tagged (Myc-core) cores. (b) Immunoblot 674 
analysis of core in the MMF collected from HuH-7 cells transfected with combinations 675 
of pcDNA3 (vector) and/or core expression plasmids (e.g., encoding core
WT
, 676 
FLAG-core, and Myc-core) as indicated. The experiment was performed under 677 
non-reducing conditions. The lower bands represent core monomer (marked with a 678 
bracket on the right). The white arrowheads indicate bands corresponding to dbd-core. 679 
The black arrowheads indicate the positions of the intermediately sized core complex 680 
formed by core
WT





Figure 5. The core dimer is formed via a bond between cysteine residues at amino acid 684 
position 128. (a) Site-directed mutagenesis of JFH1
E2FL
. (b) Immunoblot analysis of 685 
core in MMFs collected from HuH-7 cells under non-reducing condition three days 686 






 (C184A), or 687 
JFH1
C128A
 (C128/184A) RNA. (c) Infectivity of culture medium collected and 688 
concentrated on day 5 post-transfection from HuH-7 cells transfected with WT, C128A, 689 
C184A, or C128/184A RNA. (d) Real-time qRT-PCR analysis of HCV RNA titers in 690 
culture medium collected at the indicated time points from HuH-7 cells transfected with 691 
WT (open circles), C128A (filled circles), C184A (open squares), C128/184A (filled 692 
squares) or PP/AA (JFH1
PP/AA
; open triangles) RNA. (e) ELISAs of core levels in 693 
culture medium collected at the indicated time points from HuH-7 cells transfected with 694 
WT or C128A RNA. Data are representative of three independent experiments (b, c) or 695 
are the means ± s.d. from three independent experiments (d, e). 696 
 697 
Figure 6. Site-directed mutagenesis has no effect on HCV replication. (a) Real-time 698 
qRT-PCR analysis of the HCV RNA titer using total cellular RNA collected at the 699 
indicated time points from cells transfected with JFH1
E2FL





 (C128A) (filled circles), JFH1
C184A
 (C184A) (open squares), JFH1
C128/184A
 701 
(C128/184A) (filled squares), or JFH1
PP/AA
 (PP/AA) (open triangles) RNA. (b) 702 
Immunoblot analysis of NS5A and GAPDH in whole cell lysate collected from cells 703 
transfected with WT, C128A, C184A or C128/184A RNA at day 3 post-transfection. (c) 704 
Confocal microscopy of the subcellular localization of the LD (green), core (blue), 705 
NS5A (red), and nucleus (DAPI) (grey) in WT- and C128A core-expressing cells on day 706 
3 post-transfection. Scale bar indicates 10 m. (d) An RNA–protein binding 707 




 using 708 
poly-U agarose as the resin. ―+RNase‖ and ―-RNase‖ indicate samples with and without 709 
RNase treatment, respectively, as described in the Materials and Methods. ―input‖ 710 
indicates 1/40 of the amount of translated product used in this assay. Data represent the 711 
means ± s.d. from three independent experiments (a) or are representative of three 712 




 core inhibits JFH1
E2FL
 particle assembly. A competitive inhibitory 715 
assay was performed with JFH1
E2FL
 (WT) and JFH1
C128A
 (C128A). (a) Real-time 716 
qRT-PCR analysis of the HCV RNA titer in HuH-7 cell culture medium three days after 717 
the cells were transfected with the indicated ratio of WT and C128A RNA. (b) 718 
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Infectivity of culture medium collected from HuH-7 cells that had been transfected with 719 
the indicated ratio of WT and C128A RNA was analyzed as described in the Materials 720 
and Methods. Data represent the means ± s.d. from three independent experiments (a) or 721 
are representative of three independent experiments (b). 722 
 723 
Figure 8. The nucleocapsid-like particle of JFH1
E2FL
 is assembled with the C-terminal 724 
region of core on the outer surface. (a) Immunoblot analysis of core in JFH1
E2FL
 725 
particles collected from sucrose density gradient fractions with high HCV RNA titers 726 
(particle) (Fig. 2a, fraction #8 to #13). Fractions were treated with 10 g/ml trypsin at 727 
37°C for 15 min in the presence or absence of 1% NP-40 (right panel). As a positive 728 
control, whole cell lysate (WCL) prepared from JFH1
E2FL
 RNA–transfected HuH-7 cells 729 
in lysis buffer was treated with 10 g/ml trypsin at 37°C for 15 min (left panel). (b) 730 
Immunoblot analysis of core in JFH1
E2FL
 particles collected from sucrose density 731 
gradient fractions with high HCV RNA titers. Fractions were treated with the indicated 732 
concentrations of trypsin at 37°C for 10 min in the presence of 1% NP-40. Open and 733 
filled arrows indicate the positions of dbd-core and the trypsin-digested fragment, 734 
respectively. Data are representative of three independent experiments. 735 
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Supplementary Figure 1. JFH1
E2FL
 core protein. Map of the reported functional 736 
regions of the core protein from residues 1 to 191 is shown as indicated in figure. The 737 
white arrowheads indicate signal peptidase (SP) and proposed signal peptide peptidase 738 
(SPP) cleavage site by Okamoto et al. (37). The filled arrowheads represents potential 739 
trypsin cleavage sites. Cystein residues of the core are indicated by arrows. 740 
 741 
Supplementary Figure 2. Core complexes from various HCV strains. Immunoblot 742 
analysis of core from pellets containing HCV virus particles collected following 743 







 RNA–transfected HuH-7 or HuH7.5 cells under non-reducing 745 
conditions. Data are representative of three independent experiments. 746 
 747 
Supplementary Figure 3. Analysis of core complex in microsomal membrane fractions 748 





), or pcDNA3-C-E1/25 (C-E1/25), bearing full length 750 
core and the N-terminal 25 amino acid sequence of E1, were subjected to non-reducing 751 
((-) -ME) and reducing ((+) -ME) SDS-PAGE and analyzed by immunoblotting 752 
against core. Open arrowheads indicate the non-specific bands observed in MMF 753 
samples in reducing condition which positions are close to the core dimers detected in 754 
non-reducing condition. (b) Immunoblot analysis of core in the MMF collected from 755 
43 
 
HuH-7 cells transfected with pcDNA3 (vector) and/or core expression plasmids 756 
(core191, FLAG-core, and Myc-core) as indicated. Samples were treated with or 757 
without 5% -mercaptoethanol (-ME). Filled arrowheads indicate the positions of the 758 
intermediate core complexes formed by core
WT
 and tagged core. Data are representative 759 
of two (a) or three (b) independent experiments. 760 
 761 
Supplementary Figure 4. Site-directed mutagenesis of amino-acid position 127 or 129 762 
had no effect on HCV replication or the production of HCV particles. (a) Immunoblot 763 
analysis of core in microsomal membrane fractions collected on day 3 post-transfection 764 




 (T127A), or JFH1
G129A
 RNA. 765 
Samples were treated with or without 5% -mercaptoethanol-ME). (b, c) Real-time 766 
qRT-PCR analysis of HCV RNA titers in total cellular RNA (b) or culture medium (c) 767 
collected on day 5 post-transfection. Data are representative of three independent 768 
experiments (a) or are the means ± s.d. from three independent experiments (b, c). 769 
 770 
Supplementary Figure 5. Analysis of core C128S mutant. (a) Real-time qRT-PCR 771 
analysis of HCV RNA titers in culture medium collected at the indicated time points 772 
from HuH-7 cells transfected with JFH1
E2FL
 (WT, open circles) or JFH1
C128S
 (C128S, 773 
filled circles) RNA. (b) Real-time qRT-PCR analysis of the HCV RNA titer using total 774 
44 
 
cellular RNA collected at the indicated time points from cells transfected with WT 775 
(open circles) or (C128S) (filled circles). (c) Immunoblot analysis of core in microsomal 776 
membrane fraction collected on day 3 post-transfection from cells transfected with 777 
JFH1
E2FL
 (WT) or JFH1
C128S
 RNA (C128S). (d) Infectivity of culture medium collected 778 
and concentrated on day 5 post-transfection from HuH-7 cells transfected with WT or 779 
C128S RNA. (e) Confocal microscopy of the subcellular localization of the LD (green), 780 





 RNA (C128S) on day 3 post-transfection. Data are the means ± s.d. 782 
from three independent experiments (c, b) or are representative of three independent 783 
experiments (c, d, e). 784 
 785 
Supplementary Figure 6. Subcellular localization of HCV proteins. Confocal 786 
microscopy of the subcellular localizations of the lipid droplet (LD), core, NS5A, and 787 
the nucleus (DAPI) three days post-transfection with JFH1
C184A
 (C184A) or 788 
JFH1
C128/184A
 (C128/184A). Scale bar indicates 10 m. Data are representative of three 789 
independent experiments. 790 
 791 
Supplementary Figure 7. Transfection of various amounts of HCV RNA had no 792 
45 
 
effect on HCV replication. (a) Real-time qRT-PCR analysis of the HCV RNA titer in 793 
total cellular RNA collected on day 3 post-transfection from HuH-7 cells transfected 794 
with the indicated RNA ratio of JFH1
E2FL
 (WT) or JFH1
C128A
 (C128A) RNA. (b) 795 
Real-time qRT-PCR analysis of the HCV RNA titer in total cellular RNA (open bars) or 796 
culture medium (filled circles) collected on day 3 post-transfection from HuH-7 cells 797 
transfected with the indicated amount of JFH1
E2FL
 RNA. (d)Real-time qRT-PCR 798 
analysis of the HCV RNA titer in total cellular RNA (open bars) or culture medium 799 
(filled circles) collected on day 3 post-transfection from HuH-7 cells transfected with 800 
the indicated ratio of WT and JFH1
dc3
 (dc3) RNA. (c, e) The infectivity of culture 801 
medium collected from HuH-7 cells transfected with the indicated amount of JFH1
E2FL
 802 
RNA (c) and culture medium collected from HuH-7 cells transfected with the indicated 803 
ratio of WT and JFH1
dc3
 (dc3) RNA (e) were analyzed as described in the Materials and 804 
Methods. Data are the means ± s.d. from three independent experiments (a, b, d) or are 805 
representative of three independent experiments (c, e). 806 
 807 
Supplementary Table. The sets of primers used to amplify the target genes, template 808 
plasmids used in the PCRs, restriction sites, and plasmids into which the amplified DNA 809 
fragments were inserted are shown. 810 
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Figure 1. The HCV-like particle consists of a core complex formed by a disulfide bond. (a) 13 
The infectivity of the pellet fraction collected from concentrated culture medium from 14 
JFH1
E2FL
 RNA–transfected HuH-7 cells was analyzed as described in the Materials and 15 
Methods. “input” represents the same volume of concentrated culture medium used to pellet 16 
the virus-like particles. (b) Immunoblot analysis of the core in pellets containing JFH1
E2FL
 17 
virus particles treated with various levels of DTT (lanes 1, 2, 3, 4, 5 and 6 represent 0, 1.56, 18 
3.13, 6.25, 12.5 and 25 mM, respectively). (c) Immunoblot analysis of core in JFH1E2FL 19 
particles collected from sucrose density gradient fractions with high HCV RNA titers 20 
(particle) (Fig. 2a, fraction #8 to #13) and treated with 5 g/ml proteinase K at 3°C for 15 21 
min in the presence or absence of 1% NP-40 (right panel). As a positive control, whole-cell 22 
lysate (WCL) prepared from JFH1E2FL RNA–transfected HuH-7 cells in lysis buffer was 23 
treated with 5 g/ml proteinase K at 37°C for 15 min (left panel). Data are representative of 24 





Figure 2. HCV nucleocapsid-like particle consists of core complex. (a) HCV RNA titer in 28 
culture medium separated on a 20-50% sucrose density gradient. Concentrated culture 29 
medium from JFH1
E2FL
 RNA–transfected HuH-7 cells were treated with RNase and 30 
separated on a 20-50% sucrose density gradient. Fractions were obtained from the bottom 31 
to the top of the tube (#1 to #16). The HCV RNA titer and infectivity of each fraction were 32 
analyzed by real-time qRT-PCR (for fraction #1 to #16) and counting the number of cells 33 
infected with HCV-like particle detected by immunofluorecense (for fraction #3 to #14) as 34 
described in Materials and Methods, respectively. In brief, each fraction were diluted with 35 
1x PBS and HCV-like particles were collected by ultracentrifugation, then pellets were 36 
suspended in culturing medium and used for infection. (b) HCV-like particle collected from 37 
infectious (Fig. 2a, filled arrowhead) and HCV RNA (Fig. 2a, open arrowhead) peaks were 38 
collected by ultracentrifugation and subjected to non-reducing SDS-PAGE and detected by 39 
immunoblot against core. (c) HCV-like particle collected from fraction #8 to #13 (a) were 40 
subjected to non-reducing SDS-PAGE in the presence (+) or absence (-) of 5 mM 41 
N-ethylemaleimide (NEM) and analyzed by immunoblotting against the core. Data are 42 





Figure 3. The core complex is formed at the LD and ER. (a) The LD fraction and 46 
whole-cell lysate (WCL) were collected from JFH1
E2FL
 RNA–transfected HuH-7 cells on 47 
day 5 post-transfection. Immunoblot analysis of the LD marker adipose 48 
differentiation-related protein (ADRP) and the ER marker calnexin in the LD fraction 49 
(upper panel). Immunoblot analysis of core in the LD fraction treated with or without 50 50 
mM DTT (lower panel). (b) Immunoblot analysis of core protein in the MMF and WCL 51 
collected from JFH1E2FL-producing HuH-7 cells on day 5 post-transfection in the presence 52 






Figure 4. The core complex consists of a core dimer. (a) Schematic of wild-type, 57 
FLAG-tagged (FLAG-core), and Myc-tagged (Myc-core) cores. (b) Immunoblot analysis 58 
of core in the MMF collected from HuH-7 cells transfected with combinations of pcDNA3 59 
(vector) and/or core expression plasmids (e.g., encoding coreWT, FLAG-core, and 60 
Myc-core) as indicated. The experiment was performed under non-reducing conditions. The 61 
lower bands represent core monomer (marked with a bracket on the right). The white 62 
arrowheads indicate bands corresponding to dbd-core. The black arrowheads indicate the 63 
positions of the intermediately sized core complex formed by core
WT
 and tagged core. Data 64 





Figure 5. The core dimer is formed via a bond between cysteine residues at amino acid 68 
position 128. (a) Site-directed mutagenesis of JFH1
E2FL
. (b) Immunoblot analysis of core in 69 







 (C184A), or JFH1
C128A
 71 
(C128/184A) RNA. (c) Infectivity of culture medium collected and concentrated on day 5 72 
post-transfection from HuH-7 cells transfected with WT, C128A, C184A, or C128/184A 73 
RNA. (d) Real-time qRT-PCR analysis of HCV RNA titers in culture medium collected at 74 
the indicated time points from HuH-7 cells transfected with WT (open circles), C128A 75 
(filled circles), C184A (open squares), C128/184A (filled squares) or PP/AA (JFH1PP/AA; 76 
open triangles) RNA. (e) ELISAs of core levels in culture medium collected at the indicated 77 
time points from HuH-7 cells transfected with WT or C128A RNA. Data are representative 78 
of three independent experiments (b, c) or are the means ± s.d. from three independent 79 





Figure 6. Site-directed mutagenesis has no effect on HCV replication. (a) Real-time 83 
qRT-PCR analysis of the HCV RNA titer using total cellular RNA collected at the indicated 84 
time points from cells transfected with JFH1
E2FL
 (WT) (open circles), JFH1
C128A
 (C128A) 85 
(filled circles), JFH1
C184A
 (C184A) (open squares), JFH1
C128/184A
 (C128/184A) (filled 86 
squares), or JFH1PP/AA (PP/AA) (open triangles) RNA. (b) Immunoblot analysis of NS5A 87 
and GAPDH in whole cell lysate collected from cells transfected with WT, C128A, C184A 88 
or C128/184A RNA at day 3 post-transfection. (c) Confocal microscopy of the subcellular 89 
localization of the LD (green), core (blue), NS5A (red), and nucleus (DAPI) (grey) in WT- 90 
and C128A core-expressing cells on day 3 post-transfection. Scale bar indicates 10 m. (d) 91 
An RNA–protein binding precipitation assay was performed with in vitro translated coreWT 92 
and core
C128A
 using poly-U agarose as the resin. “+RNase” and “-RNase” indicate samples 93 
with and without RNase treatment, respectively, as described in the Materials and Methods. 94 
“input” indicates 1/40 of the amount of translated product used in this assay. Data represent 95 
the means ± s.d. from three independent experiments (a) or are representative of three 96 







 core inhibits JFH1
E2FL
 particle assembly. A competitive inhibitory 100 
assay was performed with JFH1
E2FL
 (WT) and JFH1
C128A
 (C128A). (a) Real-time qRT-PCR 101 
analysis of the HCV RNA titer in HuH-7 cell culture medium three days after the cells were 102 
transfected with the indicated ratio of WT and C128A RNA. (b) Infectivity of culture 103 
medium collected from HuH-7 cells that had been transfected with the indicated ratio of 104 
WT and C128A RNA was analyzed as described in the Materials and Methods. Data 105 
represent the means ± s.d. from three independent experiments (a) or are representative of 106 





Figure 8. The nucleocapsid-like particle of JFH1
E2FL
 is assembled with the C-terminal 110 
region of core on the outer surface. (a) Immunoblot analysis of core in JFH1E2FL particles 111 
collected from sucrose density gradient fractions with high HCV RNA titers (particle) (Fig. 112 
2a, fraction #8 to #13). Fractions were treated with 10 g/ml trypsin at 37°C for 15 min in 113 
the presence or absence of 1% NP-40 (right panel). As a positive control, whole cell lysate 114 
(WCL) prepared from JFH1E2FL RNA–transfected HuH-7 cells in lysis buffer was treated 115 
with 10 g/ml trypsin at 37°C for 15 min (left panel). (b) Immunoblot analysis of core in 116 
JFH1
E2FL
 particles collected from sucrose density gradient fractions with high HCV RNA 117 
titers. Fractions were treated with the indicated concentrations of trypsin at 37°C for 10 min 118 
in the presence of 1% NP-40. Open and filled arrows indicate the positions of dbd-core and 119 
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Supplementary Figure 1. JFH1
E2FL
 core protein. Map of the reported functional 15 
regions of the core protein from residues 1 to 191 is shown as indicated in figure. The 16 
white arrowheads indicate signal peptidase (SP) and proposed signal peptide peptidase 17 
(SPP) cleavage site by Okamoto et al. (37). The filled arrowheads represents potential 18 





Supplementary Figure 2. Core complexes from various HCV strains. Immunoblot 22 
analysis of core from pellets containing HCV virus particles collected following 23 





J6/JFH1, or J6/JFH1AAA99 RNA–transfected HuH-7 or HuH7.5 cells under non-reducing 25 





Supplementary Figure 3. Analysis of core complex in microsomal membrane fractions 29 





), or pcDNA3-C-E1/25 (C-E1/25), bearing full length 31 
core and the N-terminal 25 amino acid sequence of E1, were subjected to non-reducing 32 
((-) -ME) and reducing ((+) -ME) SDS-PAGE and analyzed by immunoblotting 33 
against core. Open arrowheads indicate the non-specific bands observed in MMF 34 
samples in reducing condition which positions are close to the core dimers detected in 35 
non-reducing condition. (b) Immunoblot analysis of core in the MMF collected from 36 
HuH-7 cells transfected with pcDNA3 (vector) and/or core expression plasmids 37 
(core191, FLAG-core, and Myc-core) as indicated. Samples were treated with or 38 
without 5% -mercaptoethanol (-ME). Filled arrowheads indicate the positions of the 39 
intermediate core complexes formed by coreWT and tagged core. Data are representative 40 





Supplementary Figure 4. Site-directed mutagenesis of amino-acid position 127 or 129 44 
had no effect on HCV replication or the production of HCV particles. (a) Immunoblot 45 
analysis of core in microsomal membrane fractions collected on day 3 post-transfection 46 
from cells transfected with JFH1E2FL (WT), JFH1T127A (T127A), or JFH1G129A RNA. 47 
Samples were treated with or without 5% -mercaptoethanol-ME). (b, c) Real-time 48 
qRT-PCR analysis of HCV RNA titers in total cellular RNA (b) or culture medium (c) 49 
collected on day 5 post-transfection. Data are representative of three independent 50 





Supplementary Figure 5. Analysis of core C128S mutant. (a) Real-time qRT-PCR 54 
analysis of HCV RNA titers in culture medium collected at the indicated time points 55 
from HuH-7 cells transfected with JFH1E2FL (WT, open circles) or JFH1C128S (C128S, 56 
filled circles) RNA. (b) Real-time qRT-PCR analysis of the HCV RNA titer using total 57 
cellular RNA collected at the indicated time points from cells transfected with WT 58 
(open circles) or (C128S) (filled circles). (c) Immunoblot analysis of core in microsomal 59 
membrane fraction collected on day 3 post-transfection from cells transfected with 60 
JFH1
E2FL
 (WT) or JFH1
C128S
 RNA (C128S). (d) Infectivity of culture medium collected 61 
and concentrated on day 5 post-transfection from HuH-7 cells transfected with WT or 62 
C128S RNA. (e) Confocal microscopy of the subcellular localization of the LD (green), 63 
core (blue), NS5A (red), and nucleus (DAPI) (grey) in cells transfected with JFH1E2FL 64 
(WT) or JFH1
C128S
 RNA (C128S) on day 3 post-transfection. Data are the means ± s.d. 65 
from three independent experiments (c, b) or are representative of three independent 66 





Supplementary Figure 6. Subcellular localization of HCV proteins. Confocal 70 
microscopy of the subcellular localizations of the lipid droplet (LD), core, NS5A, and 71 
the nucleus (DAPI) three days post-transfection with JFH1
C184A
 (C184A) or 72 
JFH1
C128/184A
 (C128/184A). Scale bar indicates 10 m. Data are representative of three 73 





Supplementary Figure 7. Transfection of various amounts of HCV RNA had no 77 
effect on HCV replication. (a) Real-time qRT-PCR analysis of the HCV RNA titer in 78 
total cellular RNA collected on day 3 post-transfection from HuH-7 cells transfected 79 
with the indicated RNA ratio of JFH1E2FL (WT) or JFH1C128A (C128A) RNA. (b) 80 
Real-time qRT-PCR analysis of the HCV RNA titer in total cellular RNA (open bars) or 81 
culture medium (filled circles) collected on day 3 post-transfection from HuH-7 cells 82 
transfected with the indicated amount of JFH1
E2FL
 RNA. (d)Real-time qRT-PCR 83 
analysis of the HCV RNA titer in total cellular RNA (open bars) or culture medium 84 
(filled circles) collected on day 3 post-transfection from HuH-7 cells transfected with 85 
the indicated ratio of WT and JFH1dc3 (dc3) RNA. (c, e) The infectivity of culture 86 
medium collected from HuH-7 cells transfected with the indicated amount of JFH1
E2FL
 87 
RNA (c) and culture medium collected from HuH-7 cells transfected with the indicated 88 
ratio of WT and JFH1
dc3
 (dc3) RNA (e) were analyzed as described in the Materials and 89 
Methods. Data are the means ± s.d. from three independent experiments (a, b, d) or are 90 





Supplementary Table. The sets of primers used to amplify the target genes, template 94 
plasmids used in the PCRs, restriction sites, and plasmids into which the amplified DNA 95 
fragments were inserted are shown. 96 
